MedTrace Logo

Interstage Assessment of Remnant Liver Function in ALPPS

NCT02846441 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2016-07-28

No results posted yet for this study

Summary

Post-hepatectomy liver failure is one of the most feared complications by hepatic surgeons. When size of the future liver remnant (FLR) is regarded to be not sufficient to sustain post-hepatectomy liver function, techniques as preoperative portal vein embolization or two-stage hepatectomy/associating liver partition and portal vein ligation (ALPPS) can be performed. ALPPS induces rapid and extensive hypertrophy by portal vein ligation and in situ liver splitting. To date, feasibility of the second stage of ALPPS has been assessed only on the basis of standardized future liver remnant or future liver remnant on body weight. However, decrease of liver function between stages, measured by means of laboratory parameters, has been demonstrated to be associated with higher 90-day mortality, regardless of FLR volume. In other words, this volumetric increase may not reflect the increase of liver function.

Conditions

  • Liver Failure

Interventions

PROCEDURE

hepatobiliary scintigraphy

99mTc-mebrofenin hepatobiliary scintigraphy with single photon emission computed tomography (SPECT)

Sponsors & Collaborators

  • Hospital Italiano de Buenos Aires

    lead OTHER

Principal Investigators

  • eduardo de santibanes, MD, PhD · Hospital Italiano de Buenos Aires

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2016-03-31
Completion
2016-06-30

Countries

  • Argentina

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02846441 on ClinicalTrials.gov